Investors are closely monitoring biotechnology company, Amgen Inc. (AMGN), due to a variety of factors including stock performance, dividends, recent announcements, and potential revenue growth. The company has announced its Q3 earnings and a 2025 Q4 dividend, with critics quickly voicing their opinions on the recent price dip and examining the company’s valuation following a 1-month momentum. Several financial groups and advisories, such as Bridgewealth Advisory Group and Simon Quick Advisors, have recently increased their holdings in AMGN. However, Earnings Preview suggests a potential decline in Q3 earnings while Fisher Funds Management sold a large chunk of their shares. The launch of AmgenNow and their breakthrough in Cardiovascular Studies are highlighted. AMGN has shown some stock market resilience despite some dips.
Amgen has also announced top-line results from the ASCEND Study of Rocatinlimab and significant expansion of U.S. manufacturing, creating hundreds of new jobs. Analysts project a strong pipeline of therapies reinforcing a bullish outlook for the company. Implications of FDA approval of their drug for chronic inflammatory sinus disease is also discussed. Nevertheless, Bank of America Securities maintains a sell rating on AMGN.
Amgen AMGN News Analytics from Mon, 23 Jun 2025 07:00:00 GMT to Sat, 01 Nov 2025 11:46:28 GMT - Rating 5 - Innovation 8 - Information 8 - Rumor 4
